Sees 2024 adjusted EBITDA $140M-$155M. The company said, “During the second quarter, these dynamics drove an acceleration in revenue growth and record profitability levels. We are updating our full year outlook to reflect this improving momentum and continue to believe we are on a clear path toward serving tens of millions of customers as we scale this increasingly powerful and efficient model.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- HIMS Upcoming Earnings Report: What to Expect?
- Truist says FDA GLP-1 adverse events report ‘likely a non-event’ for Hims & Hers
- FDA warns of possible overdoses with compounded semaglutide injections
- Hims & Hers lower after FDA warns of dosing errors with Ozempic
- Hims and Hers Health call volume above normal and directionally bullish